Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
News|Articles|January 2, 2005
- Pharmaceutical Technology-01-02-2005
- Volume 29
- Issue 1
The Pipeline Crisis
Committees make prudent decisions and avoid mistakes, but they're afraid of the new.
Advertisement
Articles in this issue
almost 22 years ago
An Overview of the Effect of Moisture on Compaction and Compressionalmost 22 years ago
The Outsourcing Advantages in Formulation Developmentalmost 22 years ago
Drug Safety and Access Top Policy Concerns for 2005almost 22 years ago
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Testalmost 22 years ago
Patheon Places Big Bet with Mova Acquisitionalmost 22 years ago
January 2005almost 22 years ago
In the Spotlight-January 2005Advertisement
Related to this article
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5